91759-69-2

Basic information

• Product Name: 5-(3,4-Dimethoxy-phenyl)-4-phenyl-4H-[1,2,4]triazole-3-thiol
• Synonyms: 5-(3,4-Dimethoxy-phenyl)-4-phenyl-4H-[1,2,4]triazole-3-thiol
• CAS NO: 91759-69-2
• Molecular Formula: C₁₆H₁₅N₃O₂S
• Molecular Weight: 313.38
• Mol File: 91759-69-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(3,4-Dimethoxy-phenyl)-4-phenyl-4H-[1,2,4]triazole-3-thiol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3,4-Dimethoxy-phenyl)-4-phenyl-4H-[1,2,4]triazole-3-thiol(91759-69-2)
• EPA Substance Registry System: 5-(3,4-Dimethoxy-phenyl)-4-phenyl-4H-[1,2,4]triazole-3-thiol(91759-69-2)

Safety Data

• Hazardous Substances Data: 91759-69-2(Hazardous Substances Data)

Upstream product

• 93-07-2 Veratric acid 
• 3943-77-9 ethyl veratrate 
• 41764-74-3 3,4-dimethoxybenzohydrazide 
• 103-72-0 phenyl isothiocyanate 
• 91759-67-0 C₁₆H₁₇N₃O₃S 

Downstream Products

• 91759-73-8 2-(5-(3,4-dimethoxyphenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetic acid 
• 91759-75-0 [5-(3,4-Dihydroxy-phenyl)-4-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl]-acetic acid 
• 91759-72-7 ethyl 2-(5-(3,4-dimethoxyphenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetate 

Relevant articles and documents

Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity

New N-4-piperazinyl ciprofloxacin-triazole hybrids 6a-o were prepared and characterized. The in vitro antimycobacterial activity revealed that compound 6a experienced promising antimycobacterial activity against Mycobactrium smegmatis compared with the reference isoniazide (INH). Additionally, compound 6a exhibited broad spectrum antibacterial activity against all the tested strains either Gram-positive or Gram-negative bacteria compared with the reference ciprofloxacin. Also, compounds 6g and 6i displayed considerable antifungal activity compared with the reference ketoconazole. DNA cleavage assay of the highly active compounds 6c and 6h showed a good correlation between the Mycobactrium cleaved DNA gyrase assay and their in vitro antimycobactrial activity. Moreover, molecular modeling studies were done for the designed ciprofloxacin derivatives to predict their binding modes towards Topoisomerase II enzyme (PDB: 5bs8).

New 1,2,4-triazole-Chalcone hybrids induce Caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells

A series of novel 1, 2, 4-triazole/chalcone hybrids was prepared and identified with different spectroscopic techniques. The prepared compounds showed remarkable cytotoxic activity against different cancer cell lines. Compounds 24, 25, 27, 41 and 47 had shown the highest cytotoxicity among the tested compounds against human lung adenocarcinoma A549 cells with IC50 ranging from 4.4 to 16.04 μM compared to cisplatin with IC50 of 15.3 μM. Flow cytometric analysis of the tested compounds showed an increase in the number of apoptotic cells in a dose-dependent manner. The further mechanistic study demonstrated that 1, 2, 4-triazole-chalcone hybrids induced apoptosis via increased level of proapoptotic protein Bax, release of cytochrome c from mitochondria and activation of caspase-3/8/9 proteins. However, general caspase inhibition by the pan-caspase inhibitor, z-VAD-fmk, significantly decreased the apoptosis induced by the tested hybrids, suggesting dependency of apoptosis on activation of the caspase-3 pathway.

THIOTRIAZOLYL DERIVATIVES

The invention relates to KvI.5 ion channel antagonists. Novel thiotriazolyl derivative compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by KvI.5 ion channels, are disclosed. Such cond